Nico: Real World Evidence in Advanced Melanoma; A National Prospective Non-Interventional Study of Nivolumab Monotherapy or in Combination with Ipilimumab in Patients with Advanced Melanoma and in Patients with Adjuvant Nivolumab Therapy

被引：0

作者：

Schadendorf, Dirk ^{[1
]}

Eigertler, Thomas ^{[2
]}

Mohr, Peter ^{[3
]}

Weichenthal, Michael ^{[4
]}

Goeppner, Daniela ^{[5
]}

Haferkamp, Sebastian ^{[6
]}

Herber, Martin ^{[7
]}

Meier, Friedegund ^{[8
,9
]}

Meiss, Frank ^{[10
]}

Pfoehler, Claudia ^{[11
]}

Schneider, Stefan W. ^{[12
]}

Terheyden, Patrick ^{[13
]}

Ulrich, Lens ^{[14
]}

Utikal, Jochen ^{[15
]}

Weishaupt, Carsten ^{[16
,17
,18
,19
]}

Gutzmer, Ralf ^{[20
]}

机构：

[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Dermatol Venerol & Allergol, Essen, Germany

[2] Eberhard Karls Univ Tuebingen, Dept Dermatol, Ctr Dermatooncol, Tubingen, Germany

[3] Elbe Clin Buxtehude, Buxtehude, Germany

[4] Univ Hosp Schleswig Holstein, Dept Dermatol, Kiel, Germany

[5] Justus Liebig Univ, Clin Dermatol & Allergol, Giessen, Germany

[6] Univ Regensburg, Dept Dermatol, Regensburg, Germany

[7] Bristol Myers Squibb GmbH & Co KGaA, Munich, Germany

[8] Tech Univ Dresden, Dresden Univ Hosp, Dept Dermatol, Dresden, Germany

[9] Tech Univ Dresden, Med Fac Carl Gustav Carus, Dresden, Germany

[10] Univ Freiburg, Fac Med, Med Ctr, Dept Dermatol, Freiburg, Germany

[11] Saarland Univ Hosp, Dept Dermatol, Homburg, Germany

[12] Univ Hosp Hamburg Eppendorf, Dept Dermatol & Venerol, Hamburg, Germany

[13] Univ Lubeck, Dept Dermatol, Lubeck, Germany

[14] Harzklinikum Dorothea Christiane Erxleben, Dept Dermatol, Quedlinburg, Germany

[15] Ruprecht Karl Univ Heidelberg, Univ Med Ctr Mannheim, Dept Dermatol Venereol & Allergol, Mannheim, Germany

[16] Univ Hosp Muenster, Dept Med Haematol A, Munster, Germany

[17] Univ Hosp Muenster, Dept Haemostaseol, Munster, Germany

[18] Univ Hosp Muenster, Dept Oncol, Munster, Germany

[19] Univ Hosp Muenster, Dept Pneumol, Munster, Germany

[20] Hannover Med Sch, Dept Dermatol & Allergy, Div Immunodermatol & Allergy Res, Hannover, Germany

来源：

ONCOLOGY RESEARCH AND TREATMENT | 2020年 / 43卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

320

引用

下载

页码：175 / 175

页数：1

共 50 条

[1] Real-world evidence in melanoma: A national, prospective, non-interventional study (NIS) of nivolumab monotherapy or in combination with ipilimumab in patients with advanced (unresected or metastatic) melanoma (NICO)
Eigentler, T.
Gutzmer, R.
Mohr, P.
Kaatz, M.
Pfohler, C.
Terheyden, P.
Ulrich, J.
Utikal, J.
Zimmer, L.
Schadendorf, D.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 159 - 159
[2] Real-world Data on advanced Melanoma: First Data from a national, prospective, non-interventional Study of Nivolumab in Combination with Ipilimumab or as Nivolumab Monotherapy (NICO)
Weichenthal, M.
Gutzmer, R.
Eigentler, T.
Mohr, P.
Goeppner, D.
Haferkamp, S.
Herber, M.
Herbst, R.
Meier, F.
Meiss, F.
Pfoehler, C.
Schneider, S. W.
Terheyden, P.
Ulrich, J.
Utikal, J.
Weishaupt, C.
Welzel, J.
Schadendorf, D.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2019, 17 : 5 - 6
[3] NICO - a national prospective non-interventional Study (NIS) with Nivolumab as Monotherapy or in combination with Ipilimumab in Patients with advanced (inoperable or metastatic) Melanoma to collect real-world data
Gutzmer, R.
Eigentler, T.
Mohr, P.
Becker, S.
Haferkamp, S.
Meiss, F.
Pfoehler, C.
Satzger, I.
Schneider, S. W.
Terheyden, P.
Ulrich, J.
Utikal, J.
Weichenthal, M.
Weishaupt, C.
Zimmer, L.
Schadendorf, D.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2018, 16 : 79 - 79
[4] Nivolumab (NIVO) monotherapy or combination therapy with ipilimumab (NIVO plus IPI) in advanced melanoma patients with brain metastases: Real-world evidence from the German non-interventional study NICO
Gutzmer, R.
Eigentler, T.
Mohr, P.
Weichenthal, M.
Duecker, P.
Gebhardt, C.
Goeppner, D.
Haferkamp, S.
Kaehler, K.
Meier, F.
Pfoehler, C.
Satzger, I.
Sickmann, T.
Sindrilaru, A.
Terheyden, P.
Ugurel, S.
Ulrich, J.
Utikal, J.
Weishaupt, C.
Schadendorf, D.
ANNALS OF ONCOLOGY, 2020, 31 : S746 - S747
[5] Use of nivolumab (NIVO) in adjuvant melanoma patients: real world data from NICO, a national prospective non-interventional study
Gutzmer, Ralf
Mohr, Peter
Eigentler, Thomas
Grimmelmann, Imke
Zimmer, Lisa
Livingstone, Elisabeth
Ugurel, Selma
Utikal, Jochen
Mueller, Verena
Goeppner, Daniela
Herbst, Rudolf
Kreuter, Alexander
Pfoehler, Claudia
Hollburg, Wiebke
Carmen, Loquai
Herber, Martin
Kaehler, Katharina C.
Weichenthal, Michael
Schadendorf, Dirk
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 3) : 236 - 237
[6] Real World Data on the Use of Nivolumab (Nivo) as Monotherapy or in Combination with Ipilimumab (Nivo plus Ipi) in the Treatment of advanced Melanoma: Interim Results of the non-interventional Study NICO
Ugurel, S.
Satzger, I.
Eigentler, T.
Mohr, P.
Goeppner, D.
Herber, M.
Herbst, R.
Kaehler, K. C.
Meier, F.
Meiss, F.
Pfoehler, C.
Sachse, M. M.
Schneider, S. W.
Terheyden, P.
Ulrich, J.
Utikal, J. S.
Welzel, J.
Schadendorf, D.
Gutzmer, R.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2020, 18 : 69 - 70
[7] Milestones in the Treatment of malignant Melanoma Nivolumab in the Adjuvant and as a Combination Therapy with Ipilimumab in Patients with advanced Melanoma
Sankawa, Yuri
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 (7-8) : 414 - 415
[8] Age-dependent Efficacy and Safety of Nivolumab (NIVO) as Monotherapy or Combination Therapy with Ipilimumab (NIVO plus IPI) in Patients with advanced Melanoma in the non-interventional Study (NIS) NICO
Schadendorf, D.
Ugurel, S.
Eigentler, T.
Mohr, P.
Wei-Chenthal, M.
Gebhardt, C.
Goppner, D.
Haferkamp, S.
Herbst, R.
Kahler, K.
Kreuter, A.
Meier, F.
Pfohler, C.
Sachse, M. M.
Sickmann, T.
Terheyden, P.
Ulrich, J.
Utikal, J. S.
Grimmel-Mann, I.
Gutzmer, R.
JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2021, 19 : 16 - 17
[9] Immunomodulatory effects of nivolumab and ipilimumab in combination or nivolumab monotherapy in advanced melanoma patients: CheckMate 038
Ribas, Antoni
Martin-Algarra, Salvador
Bhatia, Shailender
Hwu, Wen-Jen
Slingluff, Craig L.
Sharfman, William H.
Hodi, F. Stephen
Urba, Walter J.
Luke, Jason J.
Haanen, John B.
Callahan, Margaret K.
Wolchok, Jedd D.
Chasalow, Scott D.
Ross-Macdonald, Petra
Young, Tina C.
Qureshi, Anila
Horak, Christine E.
CANCER RESEARCH, 2017, 77
[10] HEALTHCARE COST COMPARISON ANALYSIS OF NIVOLUMAB IN COMBINATION WITH IPILIMUMAB VERSUS NIVOLUMAB MONOTHERAPY AND IPILIMUMAB MONOTHERAPY IN ADVANCED MELANOMA
Potluri, R.
Bhandari, H.
Ranjan, S.
Moshyk, A.
Kotapati, S.
VALUE IN HEALTH, 2019, 22 : S72 - S73

← 1 2 3 4 5 →